Devonian Health Group is trading 13% down today at $7.00 on profit-taking and normalization following a sharp rally earlier in July.
- The move follows a 1-for-60 share consolidation that previously drove a surge in the illiquid biotech stock.
- No fresh company-specific news or clinical updates have been reported, while the broader biotech sector is also pulling back.